Skip to main content
. 2022 Oct 21;9(34):2202528. doi: 10.1002/advs.202202528

Figure 3.

Figure 3

RanBP3 is a tumor suppressor and favorable prognostic biomarker in CRC. A) LiP‐SMap and mass spectrometry were used to identify the target proteins of NU2058. B) RanBP3 was proposed to be a direct target of NU2058. C) Successful knockout of RanBP3 in DLD1 and HCT15 cells. D,E) WST‐1 and colony formation assays were used to detect the effect of RanBP3 knockout on cell proliferation. F) Deletion of RanBP3 promoted the nuclear accumulation of β‐catenin in CRC cells. G,H) The effect of RanBP3 overexpression on cell proliferation was detected by WST‐1 and colony formation assays. I) Overexpression of RanBP3 reduced the nuclear accumulation of β‐catenin in CRC cells. J) Representative images and tumor curves showing that RanBP3 knockout promoted tumor growth (upper panel). Immunohistochemical analysis of Ki‐67 in tumor xenografts (lower panel). K) Tumor curve analysis and immunohistochemical staining of Ki‐67 showed that RanBP3 overexpression suppressed tumor growth. L) Representative images and expression pattern of RanBP3 in CRC tumor and adjacent normal tissues. M) Kaplan–Meier analysis showing the survival of 100 CRC patients based on tumor RanBP3 expression. N) The expression of RanBP3 predicted the survival of patients with pancreatic cancer, sarcoma, and endometrial cancer. Bars, SD; *p < 0.05; **p < 0.01; ***p < 0.001.